BridgeBio’s Bayer to Reveal Phase 3 Acoramidis Outcomes on NT-proBNP and TTR Variability
Bayer will present Phase 3 ATTRibute-CM data on acoramidis’ impact on outpatient worsening heart failure and serum TTR variability at ESC Heart Failure 2026 in Barcelona from May 9–12. Presentations cover a tafamidis indirect comparison, NT-proBNP rise attenuation to month 30 and KCCQ-OS improvements across all subgroups.
1. Conference Presentation Schedule
BridgeBio’s partner Bayer and academic investigators will deliver one late-breaking oral presentation and three moderated ePosters at ESC-HF 2026 in Barcelona from May 9–12, covering Phase 3 ATTRibute-CM data on acoramidis in outpatient worsening heart failure.
2. Key Phase 3 ATTRibute-CM Data
The presentations will detail acoramidis’ impact on temporal variability of serum transthyretin, attenuation of NT-proBNP rise through 30 months, and results from an anchored matching-adjusted indirect comparison versus tafamidis on hospitalization and mortality risks.
3. Patient-Reported and Subgroup Benefits
Additional posters will present KCCQ-OS overall summary score improvements and maintenance of heart failure–related health status with acoramidis across participant subgroups, demonstrating quality-of-life benefits beyond clinical endpoints.
4. Regulatory Approvals and Commercial Implications
Acoramidis is approved as Attruby in the US and BEYONTTRA in Europe, Japan, Switzerland and the UK; positive data releases could bolster commercial uptake through BridgeBio’s partnership with Bayer.